The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program
Vipul Jairath(Western University), Britta Siegmund(Humboldt-Universität zu Berlin), Ayhan Hilmi Çekın(Antalya Eğitim ve Araştırma Hastanesi), María T. Abreu(Icahn School of Medicine at Mount Sinai), Catherine Crosby(Pfizer (United States)), Marc Fellmann(Pfizer (Switzerland)), Bram Verstockt(Universitair Ziekenhuis Leuven), Guibao Gu(Arena Pharmaceuticals (United States)), David T. Rubin(University of California System), Abhishek Bhattacharjee(Pfizer (United States)), Charlie W. Lees(Western General Hospital), Joseph Wu(Pfizer (United States)), David C. Herman(Mayo Clinic), John Woolcott(Pfizer (United States))
Cited by 3
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k